{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophreniform%3B+Schizophrenic",
    "query": {
      "condition": "Schizophreniform; Schizophrenic"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T22:41:11.490Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01354132",
      "title": "N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenic Psychoses"
      ],
      "interventions": [
        {
          "name": "n-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 20,
      "start_date": "2011-05",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-07-05",
      "last_synced_at": "2026-06-10T22:41:11.490Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01354132"
    },
    {
      "nct_id": "NCT06041646",
      "title": "Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Schizophrenia",
        "Agitation,Psychomotor",
        "Schizo Affective Disorder",
        "Schizophreniform Disorders"
      ],
      "interventions": [
        {
          "name": "Sublingual film containing Igalmi",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioXcel Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 29,
      "start_date": "2023-10-02",
      "completion_date": "2024-04-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-06-10T22:41:11.490Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06041646"
    },
    {
      "nct_id": "NCT05025605",
      "title": "Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizo-Affective Disorder",
        "Schizophreniform; Schizophrenic",
        "Bipolar Disorder I",
        "Bipolar Disorder II"
      ],
      "interventions": [
        {
          "name": "BXCL501 80 Micrograms",
          "type": "DRUG"
        },
        {
          "name": "Placebo Film",
          "type": "DRUG"
        },
        {
          "name": "BXCL501 120 Micrograms",
          "type": "DRUG"
        },
        {
          "name": "BXCL501 60 Micrograms",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioXcel Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 140,
      "start_date": "2021-08-27",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-10T22:41:11.490Z",
      "location_count": 5,
      "location_summary": "Anaheim, California • Hialeah, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "DeSoto",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05025605"
    },
    {
      "nct_id": "NCT00734435",
      "title": "Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Schizophreniform Disorder"
      ],
      "interventions": [
        {
          "name": "zonisamide SR plus olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 26,
      "start_date": "2008-09",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2012-11-29",
      "last_synced_at": "2026-06-10T22:41:11.490Z",
      "location_count": 9,
      "location_summary": "National City, California • Orange, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00734435"
    },
    {
      "nct_id": "NCT00333177",
      "title": "Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Cognitive remediation training (CT)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Healthy behavior training (HBT)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Risperidone, administered orally (Oral Ris)",
          "type": "DRUG"
        },
        {
          "name": "Risperidone, administered via injection (RLAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 92,
      "start_date": "2006-03",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2020-03-26",
      "last_synced_at": "2026-06-10T22:41:11.490Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333177"
    }
  ]
}